271 related articles for article (PubMed ID: 22764249)
41. Methylphenidate Restores Behavioral and Neuroplasticity Impairments in the Prenatal Nicotine Exposure Mouse Model of ADHD: Evidence for Involvement of AMPA Receptor Subunit Composition and Synaptic Spine Morphology in the Hippocampus.
Contreras D; Piña R; Carvallo C; Godoy F; Ugarte G; Zeise M; Rozas C; Morales B
Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35806103
[TBL] [Abstract][Full Text] [Related]
42. Treadmill exercise and methylphenidate ameliorate symptoms of attention deficit/hyperactivity disorder through enhancing dopamine synthesis and brain-derived neurotrophic factor expression in spontaneous hypertensive rats.
Kim H; Heo HI; Kim DH; Ko IG; Lee SS; Kim SE; Kim BK; Kim TW; Ji ES; Kim JD; Shin MS; Choi YW; Kim CJ
Neurosci Lett; 2011 Oct; 504(1):35-9. PubMed ID: 21907264
[TBL] [Abstract][Full Text] [Related]
43. NK1 (TACR1) receptor gene 'knockout' mouse phenotype predicts genetic association with ADHD.
Yan TC; McQuillin A; Thapar A; Asherson P; Hunt SP; Stanford SC; Gurling H
J Psychopharmacol; 2010 Jan; 24(1):27-38. PubMed ID: 19204064
[TBL] [Abstract][Full Text] [Related]
44. Differential effects of methylphenidate and atomoxetine on intrinsic brain activity in children with attention deficit hyperactivity disorder.
Shang CY; Yan CG; Lin HY; Tseng WY; Castellanos FX; Gau SS
Psychol Med; 2016 Nov; 46(15):3173-3185. PubMed ID: 27574878
[TBL] [Abstract][Full Text] [Related]
45. Behavioural characterisation of rats exposed neonatally to bisphenol-A: responses to a novel environment and to methylphenidate challenge in a putative model of attention-deficit hyperactivity disorder.
Kiguchi M; Fujita S; Oki H; Shimizu N; Cools AR; Koshikawa N
J Neural Transm (Vienna); 2008 Jul; 115(7):1079-85. PubMed ID: 18368283
[TBL] [Abstract][Full Text] [Related]
46. Stimulant effects in attention deficit hyperactivity disorder: theoretical and empirical issues.
Denney CB
J Clin Child Psychol; 2001 Mar; 30(1):98-109. PubMed ID: 11294083
[TBL] [Abstract][Full Text] [Related]
47. Prenatal Nicotine Exposure in Rodents: Why Are There So Many Variations in Behavioral Outcomes?
Polli FS; Kohlmeier KA
Nicotine Tob Res; 2020 Oct; 22(10):1694-1710. PubMed ID: 31595949
[TBL] [Abstract][Full Text] [Related]
48. Neonatal 6-OHDA lesion model in mouse induces Attention-Deficit/ Hyperactivity Disorder (ADHD)-like behaviour.
Bouchatta O; Manouze H; Bouali-Benazzouz R; Kerekes N; Ba-M'hamed S; Fossat P; Landry M; Bennis M
Sci Rep; 2018 Oct; 8(1):15349. PubMed ID: 30337626
[TBL] [Abstract][Full Text] [Related]
49. Intravenous Prenatal Nicotine Exposure Alters METH-Induced Hyperactivity, Conditioned Hyperactivity, and BDNF in Adult Rat Offspring.
Lacy RT; Brown RW; Morgan AJ; Mactutus CF; Harrod SB
Dev Neurosci; 2016; 38(3):171-185. PubMed ID: 27287203
[TBL] [Abstract][Full Text] [Related]
50. Antihypertensive treatment during pregnancy induces long-term changes in gut microbiota and the behaviors of the attention deficit hyperactivity disorder offspring.
Li HB; Xu ML; Xia WJ; Dong YY; Peng B; Su Q; Wang XM; Yu JY; Gao YN; Wu JZ; Xu MY; Yang JB; Dai ZM; Chen L; Li Y; Bai J
Toxicol Appl Pharmacol; 2024 May; 486():116946. PubMed ID: 38679241
[TBL] [Abstract][Full Text] [Related]
51. Methylphenidate treatment in adolescent rats with an attention deficit/hyperactivity disorder phenotype: cocaine addiction vulnerability and dopamine transporter function.
Harvey RC; Sen S; Deaciuc A; Dwoskin LP; Kantak KM
Neuropsychopharmacology; 2011 Mar; 36(4):837-47. PubMed ID: 21150910
[TBL] [Abstract][Full Text] [Related]
52. Dopamine transporter density and behavioral response to methylphenidate in a hyperlocomotor rat model.
Muneoka K; Kuwagata M; Iwata M; Shirayama Y; Ogawa T; Takigawa M
Congenit Anom (Kyoto); 2006 Sep; 46(3):155-9. PubMed ID: 16922923
[TBL] [Abstract][Full Text] [Related]
53. Long Withdrawal of Methylphenidate Induces a Differential Response of the Dopaminergic System and Increases Sensitivity to Cocaine in the Prefrontal Cortex of Spontaneously Hypertensive Rats.
dos Santos Pereira M; Sathler MF; Valli Tda R; Marques RS; Ventura AL; Peccinalli NR; Fraga MC; Manhães AC; Kubrusly R
PLoS One; 2015; 10(10):e0141249. PubMed ID: 26509840
[TBL] [Abstract][Full Text] [Related]
54. Prenatal Nicotine Exposure Impairs the Proliferation of Neuronal Progenitors, Leading to Fewer Glutamatergic Neurons in the Medial Prefrontal Cortex.
Aoyama Y; Toriumi K; Mouri A; Hattori T; Ueda E; Shimato A; Sakakibara N; Soh Y; Mamiya T; Nagai T; Kim HC; Hiramatsu M; Nabeshima T; Yamada K
Neuropsychopharmacology; 2016 Jan; 41(2):578-89. PubMed ID: 26105135
[TBL] [Abstract][Full Text] [Related]
55. Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents.
Garnock-Jones KP; Keating GM
Paediatr Drugs; 2009; 11(3):203-26. PubMed ID: 19445548
[TBL] [Abstract][Full Text] [Related]
56. Effect of methylphenidate treatment during adolescence on norepinephrine transporter function in orbitofrontal cortex in a rat model of attention deficit hyperactivity disorder.
Somkuwar SS; Kantak KM; Dwoskin LP
J Neurosci Methods; 2015 Aug; 252():55-63. PubMed ID: 25680322
[TBL] [Abstract][Full Text] [Related]
57. Animal Models of Childhood Exposure to Lead or Manganese: Evidence for Impaired Attention, Impulse Control, and Affect Regulation and Assessment of Potential Therapies.
Smith DR; Strupp BJ
Neurotherapeutics; 2023 Jan; 20(1):3-21. PubMed ID: 36853434
[TBL] [Abstract][Full Text] [Related]
58. The selective norepinephrine reuptake inhibitor atomoxetine counteracts behavioral impairments in trimethyltin-intoxicated rats.
Tamburella A; Micale V; Mazzola C; Salomone S; Drago F
Eur J Pharmacol; 2012 May; 683(1-3):148-54. PubMed ID: 22426162
[TBL] [Abstract][Full Text] [Related]
59. Alterations in pain response are partially reversed by methylphenidate (Ritalin) in adults with attention deficit hyperactivity disorder (ADHD).
Treister R; Eisenberg E; Demeter N; Pud D
Pain Pract; 2015 Jan; 15(1):4-11. PubMed ID: 24134430
[TBL] [Abstract][Full Text] [Related]
60. Effects of methylphenidate on the catecholaminergic system in attention-deficit/hyperactivity disorder.
Wilens TE
J Clin Psychopharmacol; 2008 Jun; 28(3 Suppl 2):S46-53. PubMed ID: 18480677
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
